Introduction

Systemic fungal infections lead to considerable morbidity and mortality in patients with suppressed immune systems, such as HIV, cancer and transplant patients.  While the increasing size of such population groups has driven the need for effective treatments and prophylaxis, the advent of HAART and associated declining incidence among HIV patients has limited market growth. 

Scope

Overview of the epidemiology of invasive fungal infections, including detailed numerical breakdowns of at-risk patient groups and main risk factors 

Description of the main currently available antifungal products, including 2002 sales, percentage product usage and physician perception of products 

Report Highlights

The last fifteen years has seen a rapid expansion in the range of antifungal products available for the treatment of systemic mycoses. Consequently, considerations such as oral availability and cost are starting to exert an influence, although efficacy and side-effects remain the primary factors affecting product usage. 

Reasons to Purchase

Assess the total patient population at risk of acquiring an invasive fungal infection, and the factors which contribute to this increased risk 

Analyze factors contributing to prescription decisions, including detailed product profiles and usage trends of the main systemic antifungal product 

Understand trends in antifungal prophylaxis, including the total patient population receiving prophylaxis, and success rates 

Scope

Analysis based on a survey of 180 physicians, conducted across seven major markets - US, Japan, France, Germany, Italy, Spain and the UK 

Transcripts of interviews with key opinion leaders 

Report Highlights

The treatment of invasive fungal infections is changing from a specialty area, focused on specific subpopulations, to an increasingly high volume practice targeting large numbers of hospitalized and community based immunocompromised individuals. 

Despite recent advances in treatment, mortality rates of invasive fungal infections remain unacceptably high. Fast, accurate diagnosis remains a key obstacle in the two most common pathogen groups, Candida and Aspergillus. 

January 2004, 390 pages 

Publisher: Datamonitor Infectious Diseases Reports 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases_Reports_2004.html#a553